Disease · HP_0012758
Neurodevelopmental delay
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Neurodevelopmental delay. Diseases, record HP_0012758. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012758
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Neurodevelopmental delay
- Open Targets ID
- HP_0012758
- Other names
- NDD
- Highest stage of its drugs
- Phase 3, for 2 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EPOETIN BETA | CHEMBL2109092 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| RETOSIBAN | CHEMBL429736 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DARBEPOETIN ALFA | CHEMBL1201566 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| EPOETIN ALFA | CHEMBL1201565 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FERRIC CARBOXYMALTOSE | CHEMBL2108597 | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| FERRIC DERISOMALTOSE | CHEMBL4298187 | Oligosaccharide | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| FERRIC SULFATE | CHEMBL5095046 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IRON ISOMALTOSIDE 1000 | CHEMBL4298046 | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| OXTR | Oxytocin receptor | 1 | Oxytocin receptor antagonist | Phase 3 | https://conductscience.org/library/genes/5021 | Drugs and targets |
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02292784 | Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies | Phase 3 | 98 | 2020-07-09 | Obstetric Labour, Premature | RETOSIBAN | Its record names the disease | ClinicalTrials.gov |
| NCT05504863 | RAPIDIRON Trial Follow-up Study: RAPIDIRON-KIDS Study | 538 | Iron Deficiency Anemia, Neurodevelopmental Abnormality, Autism Spectrum Disorder | FERRIC CARBOXYMALTOSE, FERRIC SULFATE | Its record names the disease | ClinicalTrials.gov | ||
| NCT00413946 | Does Erythropoietin Improve Outcome in Very Preterm Infants? | Phase 2 | 420 | Intracranial Hemorrhage, Periventricular Leukomalacia, Cerebral Palsy, Developmental Psychomotor Disorders | EPOETIN ALFA | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials10
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012758
GET https://conductscience.org/api/diseases/v1/HP_0012758/drugs